Interleukin-2: Its role in treating HIV infected patients and the possible way to produce it Prasit Faipenkhong Production group

Outlines Introduction Clinical aspect of aldesleukin (human IL-2 derivative) Production aspect aldesleukin (human IL-2 derivative) Summary

Introduction Interleukin-2 (IL-2) cytokines helper T cells (CD4+ T cells), cytotoxic T cells (T c, CD8+ T cells), natural killer cells (NK cells) induce proliferation and differentiation of CD4+ T cells and cytotoxic T cells induce B cell proliferation, stimulate macrophage activity, increase number and toxicity of NK cells production is decrease in HIV infected patients

Aldesleukin a human IL-2 derivative recombinant DNA technique absence of an N-terminal alanine, replacement of cysteine with serine at position 125, absence of glycosylation Introduction

Diagram of the amino acid sequence of aldesleukin

Aldesleukin possess immunological activities similar to those observed with native IL-2 has been approved by FDA for treating metastatic renal cell carcinoma and metastatic melanoma phase III clinical trials in HIV infected patients Introduction

Clinical aspect of aldesleukin What Does the Research Show? Who Should Use It? Pregnant Women and Children What About Side Effects? How to Use It? How to Get It?

What Does the Research Show? Immunological benefits in several clinical trials increase CD4+ cells without sustained increase in viral load Duration of intermittent IL-2 therapy appear to be important Subcutaneous, intravenous, intramuscular daily, weekly, monthly and every two months very low doses (1 million International Units, or IU) to higher doses (18 million IU)

What Does the Research Show? Subcutaneous injection is similar to intravenous infusion improvement in immunological parameter Lower dosage of IL-2 (3 MIU/day) are still effective increase CD4+ counts No difference in viral load in group receiving IL-2 + antiretroviral therapy IL-2 + HART may reduce the latent reservoir

What Does the Research Show? French regulatory agency approve a Compassionate Use Program of aldesleukin for people with CD4+ counts below 200 and HIV levels below 1,000

Who Should Use It? Can be used safely by people at all levels of CD4+ cell counts People with high detectable viral loads People with an active infection, heart problems, lung diseases, autoimmune diseases, DM, thyroid problems People facing extreme fatigue

Pregnant Women and Children Pregnant women Children

Flu-like symptoms Swelling, redness, or lumps Sinus congestion, low blood pressure, liver toxicity, swelling due to water retention, nausea and vomiting, diarrhea, peeling skin, changes in mental status, and altered blood levels including albumin, potassium, magnesium, calcium, red blood cells, and platelets Worst on the last two or three days of a five-day course What About Side Effects?

Oliguria or anuria, shortness of breath, high fever that doesn't go away with OTC drugs, major changes in mental status, faint, major swelling

How to Use It? Subcutaneous, 9-15 MIU/day, bid, five consecutive days every eight weeks The time between courses of IL-2 therapy will be increased by four-week period Continuous intravenous, 9-18 MIU/day, five consecutive days, every eight weeks

How to Get It? several ongoing studies off label use

Production aspect aldesleukin Preparing IL-2 cDNA libraries Screening and identification of IL-2 cDNA clones Cloning of IL-2 gene into M13 vector Oligonucleotide-directed Mutagenesis Screening and Identification of Mutagenized Phage Plaques Recloning of the Mutagenized IL-2 Gene for Expression in E. coli

Preparing IL-2 cDNA libraries Procedure A collection of plasmid cloning vectors carrying both complete or incomplete IL-2 cDNA

Preparing IL-2 cDNA libraries PBL or Jurkat cells mitogen Collect of mRNA for IL-2 Convert to double strand DNA (cDNA) Join into a plasmid cloning vector IL-2 cDNA libraries Transform host cells

Synthesis of cDNA

Preparing IL-2 cDNA libraries PBL or Jurkat cells mitogen Collection of mRNA for IL-2 Convert to double strand DNA (cDNA) Join into a plasmid cloning vector IL-2 cDNA libraries Transform host cells

Screening and identification of IL-2 cDNA clones To identify the colonies of host cells that carry complete IL-2 cDNA DNA hybridization, immunological assay, protein activity Rescreen with the probe, confirm by restriction mapping

DNA hybridization

Screening and identification of IL-2 cDNA clones To identify clones that carry a specific plasmid-cDNA construct DNA hybridization, immunological assay, protein activity Rescreen with the probe, full length clones were identified and confirmed by restriction mapping

Cloning of IL-2 gene into M13 vector Single stranded DNA template Procedure

Cloning of IL-2 gene into M13 vector

Oligonucleotide-directed Mutagenesis To engineer the IL-2 gene in order to get the the IL-2 derivative which has suited physical and chemical properties Cysteine125 to serine Decrease an aggregated oligomeric form when isolated from bacterial cells Decrease an aggregated inactive oligomeric form upon storage Procedure

Oligonucleotide-directed Mutagenesis M13-IL2 (double strand) M13-IL2 (single strand) Add synthetic oligonucleotide primer GATGATGCTCTGAGAAAAGGTAATC Add Klenow fragment and dNTPs Add T4 DNA ligase Transform E. coli Produce M13 plaques

Screening and Identification of Mutagenized Phage Plaques To identify clones that contain mutated sequence of IL-2 gene Procedure

Hybridization Inoculate one clone called M13-LW46 into a culture of JM103 E. coli Screening and Identification of Mutagenized Phage Plaques Digest with restriction enzyme DdeI Prepare RF-DNA from the pellet of cell culture plate

Recloning of the Mutagenized IL-2 Gene for Expression in E. coli To express the mutagenized IL-2 gene Procedure

Recloning of the Mutagenized IL-2 Gene for Expression in E. coli RF-DNA from M13-LW46Plasmid pTrp3 Ligated plasmid called pLW46 Tranform into E. coli Restriction enzyme mapping E. coli transformed with pLW46

Restriction map of ptrp3 Restriction map of pLW46

Summary Aldesleukin, human IL-2 derivative, is produced by recombinant DNA technique. It has been approved by FDA for treating certain types of kidney and skin cancer. Now, it is under phase III clinical trials in HIV infected patients. Principle of microbial growth, maximizing the efficiency of fermentation process, bioreactors, typical large-scale fermentation, harvesting microbial cells, disrupting microbial cells, and downstream processing